fig1

Interim results from ongoing Phase III placebo-controlled, randomized trial of hepcortespenlisimut-L for advanced hepatocellular carcinoma indication

Figure 1. Effect of 48-h in vitro incubation of CD4 T lymphocytes from healthy volunteers with V5 (10-6 dilution) on expression of cell activation/proliferation markers, i.e., CD69 and Ki-67, and IL-2, TNF-α, and IFN-γ. Controls are unstimulated T cells as analyzed by flow cytometry at the same time. Except IL-2 expression, all other parameters were statistically distinct in V5-treated cells vs. controls

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/